Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $1.8 billion, employees in more than 60 countries, and more than 10,000 employees worldwide.

	NONCLINICAL DEVELOPMENT (Toxicology, Research Products, Analytical Services) Managed 443 compound development programs (>250 IND/CTA enabling), with over 100 different sponsors, which led to 41 IND/CTA applications in 2009 Performed best-in-class productivity cycle times: FIA to FIH in 22 weeks Dedicated Capacity Agreements with several major pharma customers Greater than 2.5M sq ft of research space
	CLINICAL DEVELOPMENT (Clinical Pharmacology, Clinical, Central Labs) Supported 50% of latest breakthrough cancer treatments Supported development of the top 25 currently marketed medicines 70% of clinical programs on or ahead of enrollment timelines Broad-based, scalable and market-leading, Biomarker capability 99% of samples received within stability 145 million laboratory tests; 83,000 investigator sites; 100 countries Eight Clinical Pharmacology units with ~500 beds
	PERIAPPROVAL & MARKET ACCESS Results-driven reimbursement support for >60% of the biologics market Designed and managed world’s largest safety registry ever – iPledge Team of experts dedicated to risk management and Pharmacovigilance Bi-coastal call center capabilities to deliver patient and physician support